Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

Oxford BioDynamics signs collaboration agreement with a major US biopharmaceutical company

Oxford BioDynamics
Posted on: 07 Nov 17

EpiSwitch™ technology to identify new targets and biomarkers relating to fibrotic mechanisms

 

Fibrosis associated with chronic inflammation is a serious unmet clinical need

 

Oxford BioDynamics Plc (AIM: OBD), a biotechnology company focused on the discovery and development of epigenetic biomarkers based on regulatory genome architecture, for use within the pharmaceutical and biotechnology industry, is pleased to announce that it has entered into an initial collaboration with a major US biopharmaceutical company to advance the discovery and development of novel treatments to address patients with abnormal wound healing response, leading to fibrosis. Fibrosis is a pathological feature of most chronic inflammatory diseases, which can affect nearly every tissue in the body. If left to progress, the fibrotic process eventually leads to organ malfunction and may ultimately result in death.

 

The normal healing cascade in response to tissue injury involves a series of sequential, timely and controlled physiological steps which result in successful tissue repair and restoration of normal function. Failure to control the multifaceted and complex healing process can lead to considerable tissue remodelling resulting in the replacement of functional tissue with permanent fibrous scar tissue.

 

Under the terms of the collaboration agreement, the US biopharmaceutical company will be granted access to OBD’s unique EpiSwitch™ technology for use in the analysis of structure-function of genome architecture and new insights into fibrotic mechanisms, new targets and new biomarkers. This will support the development of novel therapeutic candidates and next-generation companion diagnostics, and enable patient population stratification for clinical trials in the area of fibrosis.

 

Christian Hoyer Millar, Chief Executive Officer of Oxford BioDynamics, said:

 

“We are pleased to be collaborating with a major global biopharma company to support the development of potential novel drug candidates, and the identification of patients suitable for a new fibrosis treatment. This new collaboration is further evidence of broad adoption of our validated proprietary technology EpiSwitch™ for practical use in highly challenging therapeutic development programmes.”

 

-ENDS-

 

 

Oxford BioDynamics Plc

 

+44 (0)1865 518910

Christian Hoyer Millar, CEO

 

 

Paul Stockdale, CFO

 

 

 

 

 

Stifel Nicolaus Europe Limited

 

+44 (0)20 7710 7600

Nominated Advisor and Broker

 

 

David Arch

 

 

Jonathan Senior

 

 

Peter Lees

 

 

Ben Maddison

 

 

 

 

 

Shore Capital

 

+44 (0)20 7408 4090

Joint Broker 

 

 

Stephane Auton

 

 

Edward Mansfield

 

 

 

 

 

FTI Consulting  

 

+44 (0)20 3727 1000

Financial Public Relations Advisor

 

 

Julia Phillips

 

 

Brett Pollard

 

 

Natalie Garland-Collins

 

 

 

 

Notes for Editors

 

About Oxford BioDynamics Plc

 

Oxford BioDynamics Plc (AIM: OBD) ("Oxford BioDynamics") is a biotechnology company focused on the discovery and development of epigenetic biomarkers for use within the pharmaceutical and biotechnology industry. 

 

The Company’s award-winning, proprietary technology platform, EpiSwitch™, aims to accelerate the drug discovery and development process, improve the success rate of therapeutic product development and take advantage of the increasing importance of personalised medicine. 

 

In particular, EpiSwitch™ can reduce time to market, failure rates and the costs at every stage of drug discovery.  Additionally, the technology provides significant insights into disease mechanisms for drug discovery and product re‐positioning programmes, and enables the personalisation of therapeutics for patients in the context of challenging pricing environments where improved clinical outcomes are critical.

 

Oxford BioDynamics is headquartered in the UK, and listed on the London Stock Exchange’s AIM under the ticker "OBD".  For more information please visit www.oxfordbiodynamics.com.

Editor's Details

Mike Wood
PharmiWeb.com
www.pharmiweb.com
editor@pharmiweb.com

Last updated on: 07/11/2017

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.